119 related articles for article (PubMed ID: 9013191)
21. N2,N4,N6-tri(hydroxymethyl)-N2,N4,N6-trimethylmelamine (trimelamol) is an efficient DNA cross-linking agent in vitro.
Jackson C; Hartley JA; Jenkins TC; Godfrey R; Saunders R; Thurston DE
Biochem Pharmacol; 1991 Nov; 42(11):2091-7. PubMed ID: 1958227
[TBL] [Abstract][Full Text] [Related]
22. Synthesis and cytotoxicity of potential tumor-inhibitory analogues of trimelamol (2,4,6-tris[(hydroxymethyl)methylamino]-1,3,5-triazine) having electron-withdrawing groups in place of methyl.
Jarman M; Coley HM; Judson IR; Thornton TJ; Wilman DE; Abel G; Rutty CJ
J Med Chem; 1993 Dec; 36(26):4195-200. PubMed ID: 8277501
[TBL] [Abstract][Full Text] [Related]
23. Randomized phase II trial of hexamethylmelamine versus pentamethylmelamine in carcinoma of the bilharzial bladder.
Gad-el-Mawla N; Ziegler JL; Hamza R; Elserafi M; Khaled H
Cancer Treat Rep; 1984 May; 68(5):793-4. PubMed ID: 6426792
[No Abstract] [Full Text] [Related]
24. Hexamethylmelamine. An evaluation of its role in the therapy of cancer.
Legha SS; Slavik M; Carter SK
Cancer; 1976 Jul; 38(1):27-35. PubMed ID: 820422
[TBL] [Abstract][Full Text] [Related]
25. Studies of the mode of action of antitumour triazenes and triazines-V. The correlation of the in vitro cytotoxicity and in vivo antitumour activity of hexamethylmelamine analogues with their metabolism.
Ross D; Langdon SP; Gescher A; Stevens MF
Biochem Pharmacol; 1984 Apr; 33(7):1131-6. PubMed ID: 6424683
[TBL] [Abstract][Full Text] [Related]
26. Antitumor effect of trimelamol against human breast carcinoma xenografts in nude mice.
Yamada Y; Kubota T; Hoshiya Y; Asanuma F; Koh J; Kitajima M; Coley H; Judson I
Oncol Rep; 1996 Jul; 3(4):613-7. PubMed ID: 21594422
[TBL] [Abstract][Full Text] [Related]
27. Phase I--II study of hexamethylmelamine plus dibromodulcitol in refractory carcinoma of the breast.
Van Amburg AL; Presant CA; Vélez-García E; Klahr C
Cancer Treat Rep; 1979 Jan; 63(1):141-2. PubMed ID: 105806
[No Abstract] [Full Text] [Related]
28. Phase II evaluation of hexamethylmelamine in advanced breast cancer: a Southwest Oncology Group study.
Fabian CJ; Rasmussen S; Stephens R; Haut A; Smith F; Balcerzak S; Tranum B
Cancer Treat Rep; 1979 Aug; 63(8):1359-61. PubMed ID: 113095
[TBL] [Abstract][Full Text] [Related]
29. Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum(IV): an orally active platinum drug.
Kelland LR; Abel G; McKeage MJ; Jones M; Goddard PM; Valenti M; Murrer BA; Harrap KR
Cancer Res; 1993 Jun; 53(11):2581-6. PubMed ID: 8388318
[TBL] [Abstract][Full Text] [Related]
30. Studies on the stability of trimelamol, a carbinolamine-containing antitumor drug.
Jackson C; Crabb TA; Gibson M; Godfrey R; Saunders R; Thurston DE
J Pharm Sci; 1991 Mar; 80(3):245-51. PubMed ID: 2051341
[TBL] [Abstract][Full Text] [Related]
31. Therapy of small cell carcinoma of the lung with hexamethylmelamine.
Huang MN; Takita H; Catane H; Yee Chen T
Oncology; 1978; 35(1):29-32. PubMed ID: 203884
[TBL] [Abstract][Full Text] [Related]
32. Failure of hexamethylmelamine as salvage therapy in ovarian epithelial adenocarcinoma resistant to combination chemotherapy.
Stehman FB; Ehrlich CE; Callangan MF
Gynecol Oncol; 1984 Feb; 17(2):189-95. PubMed ID: 6423460
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of a hexamethylmelamine and 5-fluorouracil combination in the treatment of advanced ovarian carcinoma.
Kardinal CG; Luce JK
Cancer Treat Rep; 1977 Dec; 61(9):1691-3. PubMed ID: 413624
[TBL] [Abstract][Full Text] [Related]
34. Regression of human lung tumor xenografts induced by water-soluble analogs of hexamethylmelamine.
Connors TA; Cumber AJ; Ross WC; Clarke SA; Mitchley BC
Cancer Treat Rep; 1977 Aug; 61(5):927-8. PubMed ID: 408005
[No Abstract] [Full Text] [Related]
35. Effect of phenobarbital pretreatment on the metabolism and antitumor activity of hexamethylmelamine.
Paolini A; D'Incalci M
Cancer Treat Rep; 1986 Apr; 70(4):513-6. PubMed ID: 3084083
[TBL] [Abstract][Full Text] [Related]
36. Phae II study of hexamethylmelamine in women with advanced breast cancer refractory to standard cytotoxic therapy.
Denefrio JM; Vogel CL
Cancer Treat Rep; 1978 Jan; 62(1):173-5. PubMed ID: 414835
[No Abstract] [Full Text] [Related]
37. "Role of hexamethylmelamine in the treatment of ovarian cancer: where is the needle in the haystack?".
Bruckner HW
Cancer Treat Rep; 1987 Jun; 71(6):666-8. PubMed ID: 3107816
[No Abstract] [Full Text] [Related]
38. In vitro cytotoxicity of imidazolyl-1,3,5-triazine derivatives.
Yaguchi S; Izumisawa Y; Sato M; Nakagane T; Koshimizu I; Sakita K; Kato M; Yoshioka K; Sakato M; Kawashima S
Biol Pharm Bull; 1997 Jun; 20(6):698-700. PubMed ID: 9212994
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and safety of topotecan in the treatment of advanced ovarian carcinoma.
ten Bokkel Huinink W; Carmichael J; Armstrong D; Gordon A; Malfetano J
Semin Oncol; 1997 Feb; 24(1 Suppl 5):S5-19-S5-25. PubMed ID: 9122738
[TBL] [Abstract][Full Text] [Related]
40. Pentamethylmelamine (PMM): Phase I clinical and pharmacokinetic studies.
Muindi JR; Newell DR; Smith IE; Harrap KR
Br J Cancer; 1983 Jan; 47(1):27-33. PubMed ID: 6401427
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
